Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBG 2000-1: Tailored vs Standard FEC in Breast Cancer
NCT03888677Phase 3Completed
- Start
- Feb 2001
- Primary completion
- Aug 2003
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 3, randomised, open-label trial of epirubicin and cyclophosphamide in breast cancer (3 arms). Primary endpoint: Distant disease-free survival. Started Feb 2001; status: completed.
02
Drugs
epirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03888677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888677.